Calcipotriene and betamethasone dipropionate (Taclonex®/Taclonex Scalp®) is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and older.

The use of calcipotriene and betamethasone dipropionate (Taclonex®/Taclonex Scalp®) requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

Calcipotriene and betamethasone dipropionate (Taclonex®/Taclonex Scalp®) is a combination of calcipotriene and betamethasone dipropionate. Calcipotriene is a synthetic analog of vitamin D3. Calcipotriene inhibits keratinocyte proliferation and...
induces terminal differentiation of keratinocytes which reverses the abnormal keratinocyte change in psoriasis. Betamethasone dipropionate is a steroid that induces phospholipase A2 inhibitory proteins. These proteins inhibit the release of arachidonic acid, which is the precursor to inflammatory mediators such as prostaglandins and leukotrienes.

Policy Guideline Inclusion

Calcipotriene and betamethasone dipropionate (Taclonex®/Taclonex Scalp®) is approved when both of the following inclusion criteria are met:

- Documentation of psoriasis vulgaris in adults 18 years of age or older
- Documentation of the trial and failure of/intolerance to concurrent use of calcipotriene (Dovonex®) and a topical betamethasone product

Policy Guideline Exclusion

Calcipotriene and betamethasone dipropionate (Taclonex®/Taclonex Scalp®) is denied when any of the following exclusion criteria are present:

- No documentation of psoriasis vulgaris in adults 18 years of age or older
- No documentation of the trial and failure of/intolerance to concurrent use of calcipotriene (Dovonex®) and a topical betamethasone product

Policy List of Applicable Drugs

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taclonex/Taclonex Scap</td>
<td>Calcipotriene and betamethasone dipropionate</td>
</tr>
</tbody>
</table>

Dosing and Administration

Refer to the specific manufacturer's prescribing information for administration and dosage details for each specific agent.

Policy References


Calcipotriene and betamethasone dipropionate (Taclonex®/Taclonex Scalp®). In: Drugdex [online through Micromedex Healthcare Series]. Greenwood


Policy Link to Related Policies

The Policy Bulletins on this web site were developed to assist AmeriHealth and its subsidiaries ("AmeriHealth") in administering the provisions of the respective benefit programs, and do not constitute a contract. If you are an AmeriHealth member, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. AmeriHealth does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical
advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of AmeriHealth. If you have a specific medical condition, please consult with your doctor. AmeriHealth reserves the right at any time to change or update its Policy Bulletins. ©2008 AmeriHealth, Inc. All Rights Reserved. Current Procedural Terminology ©2008 American Medical Association. All Rights Reserved.